

Full-year 2023 results



“2023 was a turning-point year for Sanofi, paving the way for our scientific leadership in Immunology. Coupled with our AI at-scale ambitions, we go forward as a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.”

Paul Hudson
Chief Executive Officer, Sanofi

Full-year 2023 company sales

€43,070m (+5.3% at constant exchange rates, +0.2% on a reported basis)

Full-year 2023 business earnings per share

€8.11 (+5.4% at constant exchange rates, -1.8% on a reported basis)

Sales by global business unit



Specialty Care
€18,040m



Vaccines
€7,474m



General Medicines
€12,376m



Consumer Healthcare
€5,180m

•

Full-year 2023 *results*

•

Sales by geography

US
€18,512m

Europe
€10,392m

Rest of the World
€14,166m

Research & Development highlights

Advancing breakthrough science



Record 12 blockbuster opportunities under clinical evaluation



More than 35 Phase 3 projects by 2025

For further information on full-year 2023 results and definitions of financial indicators, please refer to the press release issued on February 1, 2024 at: www.sanofi.com/en/investors